Literature for inhibitor I31.002: MHC II invariant chain p41 form

(Topics flags: S Structure. To select only the references relevant to a single topic, click the link above. See explanation.)

2016
1. Zavasnik-Bergant,T. and Bergant Marusic,M.
   Exogenous thyropin from p41 invariant chain diminishes cysteine protease activity and affects IL-12 secretion during maturation of human dendritic cells
   PLoS ONE11, e0150815-e0150815. PubMed  Europe PubMed DOI
2008
2. Costantino,C.M., Hang,H.C., Kent,S.C., Hafler,D.A. and Ploegh,H.L.
   Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation
   J Immunol180, 2876-2885. PubMed  Europe PubMed
2005
3. [YEAR:31-3-2005]Schneiders,A., Thiel,S., Winkler,J., Moller,P. and Koch,N.
   Antibodies generated by a novel DNA vaccination identify the MHC class III encoded BAT2 polypeptide
   Vaccine23, 2540-2550. PubMed  Europe PubMed DOI
2003
4. [YEAR:20-1-2003]Beers,C., Honey,K., Fink,S., Forbush,K. and Rudensky,A.
   Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages
   J Exp Med197, 169-179. PubMed  Europe PubMed DOI
5. [YEAR:12-2-2003]Chiva,C., Barthe,P., Codina,A., Gairi,M., Molina,F., Granier,C., Pugniere,M., Inui,T., Nishio,H., Nishiuchi,Y., Kimura,T., Sakakibara,S., Albericio,F. and Giralt,E.
   Synthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin L
   J Am Chem Soc125, 1508-1517. PubMed  Europe PubMed DOI
2002
6. [YEAR:4-11-2002]Fiebiger,E., Maehr,R., Villadangos,J., Weber,E., Erickson,A., Bikoff,E., Ploegh,H.L. and Lennon-Dumenil,A.M.
   Invariant chain controls the activity of extracellular cathepsin L
   J Exp Med196, 1263-1269. PubMed  Europe PubMed DOI
2001
7. [YEAR:1-8-2001]Lennon-Dumenil,A.M., Roberts,R.A., Valentijn,K., Driessen,C., Overkleeft,H.S., Erickson,A., Peters,P.J., Bikoff,E., Ploegh,H.L. and Bryant,P.W.
   The p41 isoform of invariant chain is a chaperone for cathepsin L
   EMBO J20, 4055-4064. PubMed  Europe PubMed DOI
2000
8. [YEAR:20-3-2000]Pierre,P., Shachar,I., Matza,D., Gatti,E., Flavell,R.A. and Mellman,I.
   Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells
   J Exp Med191, 1057-1062. PubMed  Europe PubMed DOI
1999
9. [YEAR:15-2-1999]Guncar,G., Pungercic,G., Klemencic,I., Turk,V. and Turk,D.
   Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S
   EMBO J18, 793-803. PubMed  Europe PubMed DOI  S
1998
10. [YEAR:1-12-1998]Jasanoff,A., Wagner,G. and Wiley,D.C.
    Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii
    EMBO J17, 6812-6818. PubMed  Europe PubMed DOI  S
11. Lenarcic,B. and Bevec,T.
    Thyropins - new structurally related proteinase inhibitors
    Biol Chem379, 105-111. PubMed  Europe PubMed
1997
12. Bevec,T., Stoka,V., Pungercic,G., Cazzulo,J.J. and Turk,V.
    A fragment of the major histocompatibility complex class II-associated p41 invariant chain inhibits cruzipain, the major cysteine proteinase from Trypanosoma cruzi
    FEBS Lett401, 259-261. PubMed  Europe PubMed DOI
1996
13. Bevec,T., Stoka,V., Pungercic,G., Dolenc,I. and Turk,V.
    Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L
    J Exp Med183, 1331-1338. PubMed  Europe PubMed DOI
14. Kageyama,T., Yonezawa,S., Ichinose,M., Miki,K. and Moriyama,A.
    Potential sites for processing of the human invariant chain by cathepsins D and E
    Biochem Biophys Res Commun223, 549-553. PubMed  Europe PubMed DOI